

**Platelet-Derived Growth Factor Receptors α and β
Reporter Assay System
(PDGFR α/β)**

3x32 Assays in 96-well Plate Format
Product # IB23001-32

▪

Technical Manual
(version 7.2i)

www.indigobiosciences.com

3006 Research Drive, Suite A1, State College, PA, 16801, USA

Customer Service:
814-234-1919; FAX 814-272-0152
customerserv@indigobiosciences.com

Technical Service:
814-234-1919
techserv@indigobiosciences.com



Human PDGFR α / β Reporter Assay System 3x 32 Assays in 96-well Plate Format

I. Description	
▪ The Assay System.....	3
▪ The Assay Chemistry.....	4
▪ Preparation of Test Compounds.....	4
▪ Assay Scheme.....	4
▪ Assay Performance.....	5
II. Product Components & Storage Conditions	7
III. Materials to be Supplied by the User	7
IV. Assay Protocol	
▪ A word about Inhibition-mode assay setup.....	8
▪ <i>DAY 1 Assay Protocol</i>	8
▪ <i>DAY 2 Assay Protocol</i>	10
V. Related Products	11
VI. Limited Use Disclosures	11
APPENDIX 1: Example Scheme for Serial Dilutions	12

I. Description

▪ The Assay System ▪

This assay utilizes proprietary human cells that have been engineered to provide constitutive expression of the **Human Platelet-Derived Growth Factor Receptors α and β** , referred to herein as **PDGFR α/β** . PDGFR α and PDGFR β are both single-pass transmembrane receptors that contain respective extracellular ligand-binding domains, transmembrane domains, and intracellular tyrosine kinase domains¹.

Platelet-derived growth factor (PDGF), the physiological activator of PDGFRs, consists of four polypeptide members: A, B, C and D^{1,2}. The biologically active forms of PDGF proteins are both homo-dimers and hetero-dimers of disulfide-linked polypeptides. These function to promote cell migration, proliferation, and survival². Binding of dimeric PDGF triggers conformational changes that drive the assembly of homo-dimeric (R α :R α , R β :R β) and/or hetero-dimeric (R α :R β) receptors, and the activation of their respective cytosolic tyrosine kinase domains^{1,2}. Because these reporter cells constitutively express both PDGFR α and PDGFR β , it is anticipated that all three forms of the activated receptor dimers are present. If desired, reporter cells expressing either homo-dimeric PDGFR can be made available (please inquire).

The tyrosine kinase activities of activated, dimeric PDGFR's initiate intracellular signaling cascades that include RAS-MAPK, PI3-AKT, PLC γ and STAT pathways^{2,3}. For example, activation of the PLC γ pathway leads to an increase of intracellular calcium⁴. One prominent outcome of the PDGF/PDGFR > PLC γ pathway is that calcineurin, a calcium-dependent phosphatase, dephosphorylates and activates the transcription factor NFAT⁴. It is PDGFR signal transduction *via* the Ca⁺²-calcineurin / NFAT cascade that is exploited by the reporter cells provided in this kit.

INDIGO's PDGFR α/β Reporter Cells contain the luciferase reporter gene functionally linked to tandem consensus sequences of NFAT response elements upstream of a minimal promoter. Activated NFAT binds to these response elements to initiate the formation of a complete transcription complex that drives Luc gene expression.

PDGF activates PDGFR α/β in a dose-dependent manner, thereby triggering the Ca⁺²-calcineurin/NFAT signal transduction pathway. Quantifying relative changes in luciferase activity in the treated reporter cells relative to the untreated cells provides a sensitive, dose-dependent surrogate measure of drug-induced changes in PDGFR α/β activity. Accordingly, the principal application of this reporter assay is in the screening of test materials to quantify any functional interactions, either activating or inhibitory, that they may exert against PDGFR α/β , or the coupled Ca⁺²-calcineurin/NFAT signal transduction pathway.

The clinical use of recombinant PDGF-BB has led to the successful treatment of chronic or diabetes-related non-healing lower extremity wounds⁵. In addition, PDGF-BB has also been used in clinics for reducing Parkinsonian symptoms⁵. However, dysfunctional PDGFR signaling can lead to a range of physiological disorders. For example, enhanced signaling of PDGFRs has been implicated in the pathogenesis of atherosclerosis, pulmonary fibrosis, angiogenesis, and tumorigenesis². Consequently, the PDGF receptors continue to command much interest as targets for drug development and drug safety screening.

INDIGO's Reporter Cells are transiently transfected and prepared as frozen stocks using a proprietary **CryoMite™** process. This cryo-preservation method allows for the immediate dispensing of healthy, division-competent reporter cells into assay plates. There is no need for intermediate treatment steps such as spin-and-rinse of cells, viability determinations or cell titer adjustments prior to assay setup. This assay kit provides the convenience of an all-inclusive cell-based reporter assay system for PDGFR α/β signaling. In addition to Reporter Cells, included are an optimized culture medium for use in reviving the cryopreserved cells, a culture medium for use in preparing test sample treatments, the reference physiological activator PDGF-BB, Luciferase Detection Reagents, and a cell culture-ready assay plate.

¹ Kazlauskas, K, *et al.* (2017) PDGFs and their Receptors. *Gene*. May 30; **614**: 1–7.

² Wu E, *et al.* (2008) Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells. *PLoS One*. 3(11): e3794. doi:10.1371/journal.pone.0003794

³ Ying HZ, *et al.* (2017) PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review). *Molecular Medicine Reports* **16**: 7879-7889.

⁴ Park JY, *et al.* (2020) The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Disease, *Frontiers in Immunology*.:doi:10.3389/fimmu.2020.00195.

⁵ Niu A, *et al.* (2020) Development of a novel reporter gene assay for platelet-derived growth factor-BB bioactivity. *Biologicals* **63**: 68-73.

▪ The Assay Chemistry ▪

INDIGO's receptor assay kits capitalize on the extremely low background, high-sensitivity, and broad linear dynamic range of bio-luminescence reporter gene technology.

Reporter Cells incorporate the cDNA encoding beetle luciferase, a 62 kD protein originating from the North American firefly (*Photinus pyralis*). Luciferase catalyzes the mono-oxidation of D-luciferin in a Mg^{+2} -dependent reaction that consumes O_2 and ATP as co-substrates to yield oxyluciferin, AMP, PP_i , CO_2 , and photon emission. Luminescence intensity of the reaction is quantified using a luminometer and is reported in terms of Relative Light Units (RLU's).

This assay kit features a luciferase detection reagent specially formulated to provide stable light emission between 10 and 90+ minutes after initiating the luciferase reaction.

Incorporating a 10-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.

▪ Preparation of Test Compounds ▪

Small molecule test compounds are typically solvated in DMSO at high concentrations; ideally 1,000x-concentrated stocks relative to the highest desired treatment concentration in the assay. Using high-concentration stocks minimizes DMSO carry-over into the assay plates. Immediately prior to setting up an assay, the master stocks are serially diluted using one of two alternative strategies:

1.) As described in *Step 7* and depicted in Appendix 1 for the reference agonist Aldosterone, **Compound Screening Medium (CSM)** may be used as the diluent to make serial dilutions of test compounds to achieve the desired final assay concentration series.

Alternatively, if test compound solubility is expected to be problematic,


2.) DMSO may be used to make serial dilutions, thereby generating 1,000x-concentrated stocks for each independent test concentration. Treatment media are then prepared using CSM to make final 1,000-fold dilutions of the prepared DMSO dilution series.

Regardless of the dilution method used, the final concentration of total DMSO carried over into assay wells should not exceed 0.4%. Significant DMSO-induced cytotoxicity can be expected above 0.4%.

NOTE: CSM is formulated to help stabilize hydrophobic test compounds in the aqueous environment of the assay mixture. Nonetheless, high concentrations of extremely hydrophobic test compounds diluted in CSM may lack long-term stability and/or solubility, especially if further stored at low temperatures. Hence, it is recommended that test compound dilutions are prepared in CSM immediately prior to assay setup and are considered to be 'single-use' reagents.

▪ Assay Scheme ▪

Figure 1. Assay workflow. *In brief*, 200 μ l of Reporter Cells is dispensed into wells of the assay plate and pre-incubated for 4-6 hours. Following the pre-incubation period, culture media are discarded and 200 μ l/well of the prepared 1x-concentration treatment media are added. Following 22 - 24 hours incubation, treatment media are discarded, and Luciferase Detection Reagent is added. The intensity of light emission (in terms of 'Relative Light Units'; RLU) from each assay well is quantified using a plate-reading luminometer.



▪ Assay Performance ▪




Figure 2. PDGFR α/β Activation dose response analyses. Activation dose-response assays were performed according to the protocol provided in this Technical Manual. 200 μ l / well of PDGFR α/β Reporter Cell suspension was dispensed into the 96-well assay plate, which was then incubated for 4 hours. The concentrated stock of PDGF-BB (provided), PDGF-AB and PDGF-CC (both from Peprotech) were further diluted using CSM to produce treatment media at the desired assay concentrations. The pre-culture media were discarded from the assay wells and 200 μ l / well of the prepared treatment media were dispensed (n = 3/conc.), including ‘untreated’ control wells. Following a 22 hr incubation period treatment media were discarded, Luciferase Detection Reagent was added, and luminescence intensity per well was quantified. Values of average relative light units (RLU) and corresponding values of standard deviation (SD), percent coefficient of variation (%CV), Fold-Activation and Z' ⁶ were determined for each treatment concentration. Non-linear regression analyses of Fold Activation vs. $\text{Log}_{10}[\text{ng/mL}]$ and EC_{50} determinations were performed using GraphPad Prism software.

⁶ Zhang JH, *et al.* (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J Biomol Screen.*:4(2), 67-73.

$$Z' = 1 - [3 * (SD^{\text{Ref } EC_{100}} + SD^{\text{Untreated}}) / (RLU^{\text{Ref } EC_{100}} - RLU^{\text{Untreated}})]$$




Figure 3. PDGFR α/β Inhibition dose-response analyses. PDGFR α/β reporter cells were co-treated with an EC₈₀ concentration of the reference activator PDGF-BB and varying concentrations of the PDGFR inhibitors BIBF-1120, Pazopanib, SU 16f, Sorafenib, AG-1296 and SU6668 (all compounds obtained from Cayman Chemical, Ann Arbor MI, USA). The range of determined IC₅₀ values is shown; (n = 3 / conc.). INDIGO's Live Cell Multiplex (LCM) Assay confirmed that no treatment concentrations were cytotoxic (data not shown). Non-linear regression analyses of RLU vs. Log₁₀[Inhibitor, nM] were plotted and IC₅₀ determinations made using GraphPad Prism software.

II. Product Components & Storage Conditions

This PDGFR α / β Reporter Assay kit contains materials to perform three distinct groups of assays in a 96-well plate format. Reagents are configured so that each group will comprise 32 assays. If desired, however, reagents may be combined to perform either 64 or 96 assays.

Reporter cells are temperature sensitive! To ensure maximal viability the tube of cells must be maintained at -80°C until immediately prior to the rapid-thaw procedure described in Step 3 of this protocol.

Assay kits are shipped on dry ice. Upon receipt of the kit transfer it to -80°C storage. If you wish to first inspect and inventory the individual kit components be sure to first transfer and submerge the tube of reporter cells in dry ice.

The aliquot of Reporter Cells is provided as a single-use reagent. Once thawed, reporter cells can NOT be refrozen, nor can they be maintained in extended culture with any hope of retaining downstream assay performance. Therefore, extra volumes of these reagents should be discarded after assay setup.

The date of product expiration is printed on the Product Qualification Insert (PQI) enclosed with each kit.

<u>Kit Components</u>	<u>Amount</u>	<u>Storage Temp.</u>
▪ PDGFR α / β Reporter Cells	3 x 0.6 mL	-80°C
▪ Cell Recovery Medium (CRM)	2 x 10.5 mL	-20°C
▪ Compound Screening Medium (CSM)	1 x 45 mL	-20°C
▪ PDGF-BB, 2 μ g/ml (in PBS/0.1%BSA) (reference activator of PDGFR's)	1 x 40 μ L	-20°C
▪ Detection Substrate	3 x 2.0 mL	-80°C
▪ Detection Buffer	3 x 2.0 mL	-20°C
▪ Plate frame	1	ambient
▪ Snap-in, 8-well strips (white, sterile, collagen-coated wells)	12	-20°C

NOTE: This Assay kit contains 8-well strips that have been collagen-coated and dried; these strip wells should be stored frozen (-20°C or -80°C) until use.

III. Materials to be Supplied by the User

The following materials must be provided by the user, and should be made ready prior to initiating the assay procedure:

DAY 1

- dry ice bucket (*Step 2*)
- cell culture-rated laminar flow hood.
- 37°C, humidified 5% CO₂ incubator for mammalian cell culture.
- 37°C water bath.
- 70% alcohol wipes
- 8-channel electronic, repeat-dispensing pipettes & sterile tips
- disposable media basins, sterile.
- sterile multi-channel media basins (such as the Heathrow Scientific "Dual-Function Solution Basin"), *or* sterilized 96 deep-well blocks (*e.g.*, Axygen Scientific, #P-2ML-SQ-C-S), *or* appropriate similar vessel for generating dilution series of reference and test compound(s).
- *Optional:* reference antagonist (refer to Fig. 3)
- *Optional:* clear 96-well assay plate, sterile, *collagen-coated*, for viewing cells on Day 2.

DAY 2 plate-reading luminometer.

IV. Assay Protocol

Please review the entire protocol before starting. Completing the assay requires an overnight incubation. *Steps 1-11* are performed on **Day 1**, requiring less than 2 hours of bench work and a 4 hour incubation step to complete. *Steps 12-17* are performed on **Day 2** and require less than 1 hour to complete.

▪ A word about Inhibition-mode assay setups ▪

Receptor inhibition assays expose the Reporter Cells to a fixed, sub-maximal concentration (typically between EC₅₀ – EC₈₅) of a known activator AND varying concentrations of the test compound(s) to be evaluated for chemical inhibition. This PDGFR α/β Assay kit includes a 2 $\mu\text{g}/\text{mL}$ stock solution of PDGF-BB, a potent physiological activator of PDGFR's, that may be used to set up inhibition-mode assays. ~ 4.5 ng/mL PDGF-BB approximates EC₈₀ in this assay. Hence, it presents a suitable concentration of activator to use when screening test materials for inhibitory activities.

Add PDGF-BB to a bulk volume of CSM, as described above. This activator-supplemented medium is then used to prepare serial dilutions of test material stocks to achieve the desired respective final assay concentrations. This is an efficient and precise method of setting up PDGFR α/β inhibition assays, and it is the method presented in *Step 7b* of this protocol.

DAY 1 Assay Protocol: All steps must be performed using aseptic technique.

1.) Remove the **2 tubes** of **Cell Recovery Medium (CRM)** from freezer storage, thaw and equilibrate to 37°C using a water bath.

2.) **Rapid Thaw of the Reporter Cells:** *First*, retrieve the two tubes of **CRM** from the 37°C water bath and sanitize their outside surfaces with a 70% ethanol swab.

Second, retrieve tubes of **Reporter Cells** from -80°C storage and place them directly into dry ice for transport to the laminar flow hood: 1 tube for 32 assay wells, 2 tubes for 64 assay wells, or 3 tubes for 96 assay wells. When ready to begin, transfer the tube(s) of reporter cells into a rack and, *without delay*, perform a rapid thaw of the frozen cells by transferring **6.4 ml** of pre-warmed CRM into each tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37°C water bath for 5 - 10 minutes. The resulting volume of cell suspension will be 7.0 ml per tube.

Third, work in the cell culture hood to *carefully* mount four sterile 8-well strips into the blank assay plate frame. Strip-wells are fragile. Note that they have keyed ends (square and round), hence, they will fit into the plate frame in only one orientation.

3.) Retrieve the tube of Reporter Cell Suspension from the water bath and sanitize the outside surface with a 70% alcohol swab.

4.) If more than one tube of Reporter cells was thawed, combine them and gently invert several times to gain a homogenous cell suspension. Dispense **200 μl** / well of cell suspension into the assay plate.

NOTE 4.1: If INDIGO's Live Cell Multiplex Assay is to be incorporated, a minimum of 3 'cell blank' wells (meaning cell-free but containing 'Compound Screening Media') must be included in the assay plate to allow quantification of plate-specific fluorescence background (refer to the LCMA Technical Manual).

NOTE 4.2: Increased well-to-well variation (= increased standard deviation!) will occur if care is not taken to prevent cells from settling in the reservoir during the dispensing period. Likewise, take care to ensure precision in dispensing exact volumes across the assay plate.

NOTE 4.3: Users sometimes wish to examine the reporter cells using a microscope. If so, the extra volume of cell suspension provided with each kit may be dispensed into a clear, preferably collagen-coated, 96-well assay plate. Continue to process this plate in identical manner to the white assay plate.

5.) Pre-incubate reporter cells. Place the assay plate into a cell culture incubator (37°C, $\geq 70\%$ humidity, 5% CO₂) for 4 - 6 hours.

6.) Near the end of the pre-incubation period remove Compound Screening Medium (CSM) from freezer storage and thaw in a 37°C water bath.

7.) Prepare the Test Compound and Reference Compound treatment media at the desired final assay concentrations: Use CSM to prepare an appropriate dilution series of the reference and test compound stocks. Prepare treatment media at the desired **final assay concentrations**. In *Step 9*, **200 μ l / well** of the prepared treatment media are dispensed into the strip-wells of the assay plate. Manage dilution volumes carefully; this assay kit provides **45 ml** of CSM.

NOTE: Total DMSO carried over into assay reactions should not exceed 0.4%.

a. Activation-mode assays. This PDGFR α/β Assay kit includes a concentrated stock of PDGF-BB, 2 μ g/ml prepared in PBS/0.1%BSA. The following 7-point treatment series, with concentrations generated using serial 3-fold dilutions, provides a complete dose-response: 20.0, 6.67, 2.22, 0.741, 0.247, 0.082, and 0.027 ng/ml. **APPENDIX 1** provides guidance for generating such a dilution series. Always include 'no treatment' control wells.

~ or ~

b. Inhibition-mode assays. When setting up inhibition assays, first supplement a bulk volume of CSM with the challenge activator PDGF-BB to achieve an EC₅₀ – EC₈₀ concentration (refer to "A word about inhibition-mode assay setup", pg. 8). The PDGF-BB supplemented CSM is then used to generate dilutions of test compound stocks to achieve the desired series of treatment concentrations.

8.) At the end of the cell pre-incubation period, discard the culture media. Because the assay plate is composed of a frame with snap-in strip-wells, the practice of physically ejecting media is NOT advised. Complete removal of the media is efficiently performed by tilting the plate on edge and aspirating media using either a single-tip, or an 8-pin manifold (*e.g.*, Wheaton Science Microtest Syringe Manifold, # 851381) affixed to a vacuum-trap apparatus. Do *not* touch the well bottom or run the tip of the aspiration device around the bottom circumference of the assay well. Such practices will result in destruction of the cells and greatly increased well-to-well variability.

9.) Dispense **200 μ l** of each treatment media into appropriate wells of the assay plate.

10.) Transfer the assay plate into a 37°C, humidified 5% CO₂ incubator for 22 - 24 hours.

NOTE: Ensure a high-humidity ($\geq 70\%$) environment within the cell culture incubator. This is critical to prevent the onset of deleterious "edge-effects" in the assay plate.

11.) For greater convenience on *Day 2*, retrieve the appropriate number of vials of **Detection Substrate and Detection Buffer** from freezer storage and place them in a dark refrigerator (4°C) to thaw overnight.

DAY 2 Assay Protocol: Subsequent manipulations do *not* require special regard for aseptic technique, and may be performed on a bench top.

12.) 30 minutes before intending to quantify receptor activity, remove **Detection Substrate** and **Detection Buffer** from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature.

NOTE: Do NOT actively warm Detection Substrate above room temperature. If these solutions were not allowed to thaw overnight at 4°C, a room temperature water bath may be used to expedite thawing.

13.) Set the plate-reader to "luminescence" mode. Set the instrument to perform a single 5 second "plate shake" prior to reading the first assay well. Read time may be set to 0.5 second (500 mSec) per well, *or less*.

14.) *Immediately before proceeding to Step 15:* To read 32 assay wells, transfer the entire volume of 1 vial of Detection Buffer into 1 vial of Detection Substrate, thereby generating a 4 ml volume of **Luciferase Detection Reagent (LDR)**. Mix gently to avoid foaming.

15.) Following 22 - 24 hours incubation in treatment media, remove media contents from each well of the assay plate (as before in *Step 8*).

16.) Add 100 µl of **LDR** to each well of the assay plate. Allow the assay plate to rest at room temperature for 5 - 10 minutes following the addition of LDR. Do not shake the assay plate during this period.

17.) Quantify luminescence.

V. Related Products

<i>Product No.</i>	<i>Product Descriptions</i>
Platelet-Derived Growth Factor Receptor α and β Assay	
IB23001-32	PDGFR α / β Assay, 3x 32 assays in 8-well strips (96-well plate format)
IB23001	PDGFR α / β Assay, 1x 96-well format assay
IB23002	PDGFR α / β Assay, 1x 384-well format assays
Bulk volumes of PDGFR α / β Assay Reagents may be custom manufactured to accommodate any scale of HTS. In addition, single receptor PDGFRα and PDGFRβ Assays can be made available upon request. Please Inquire.	

NFAT Assays (recommended for receptor specificity screening)	
IB18001-32	NFAT Reporter Assay System 3x 32 assays in 8-well strips (96-well plate format)
IB18001	NFAT Reporter Assay System 1x 96-well format assay

LIVE Cell Multiplex (LCM) Assay	
LCM-01	Reagent volumes sufficient to perform 96 Live Cell Assays in 1x96-well, or 2x48-well, or 3x32-well assay plate formats
LCM-05	Reagent in 5x bulk volume to perform 480 Live Cell Assays performed in 5 x 96-well assay plates
LCM-10	Reagent in 10x bulk volume to perform 960 Live Cell Assays performed in 10 x 96-well assay plates
INDIGlo Luciferase Detection Reagent	
LDR-10, -25, -50, -500	INDIGlo Luciferase Detection Reagents in 10 mL, 25 mL, 50 mL, and 500 mL volumes

Please refer to INDIGO Biosciences website for updated product offerings.

www.indigobiosciences.com

VI. Limited Use Disclosures

Products commercialized by INDIGO Biosciences, Inc. are for RESEARCH PURPOSES ONLY – not for therapeutic, diagnostic, or contact use in humans or animals.

“CryoMite” is a Trademark TM of INDIGO Biosciences, Inc. (State College, PA, USA)

Product prices, availability, specifications, and claims are subject to change without prior notice.

Copyright © INDIGO Biosciences, Inc. (State College, PA, USA). All Rights Reserved.

